







Economic Burden Associated with Streptococcus suis Infection Treatment in Northern Thailand: A Hospital-based Observational Study

RWD146

Ajaree Rayanakorn^{1-2*}, Wasan Katip³, Zanfina Ademi⁴⁻⁵, Kok-Gan Chan^{6-7*}

¹Faculty of Public Health, Chiang Mai University, Thailand; ²School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 47500, Bandar Sunway, Selangor, Malaysia; ³Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Thailand; ⁴Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, VIC 3052, Australia; 5School of Public Health and Preventive Medicine, Monash University; 6Division of Genetics and Molecular Biology, Faculty of Science, Institute of Biological Sciences, University of Malaya, Kuala Lumpur, Malaysia; ⁷International Genome Centre, Jiangsu University, Zhenjiang, China

*Email: ajaree.rayanakorn@cmu.ac.th; kokgan@um.edu.my

Background and Objectives



stains of an S. suis colony showing Gram-positive cocci. in a local market, Thailand Eric Gomez et al. J. Clin. Microbiol. 2014;52:2254-2258 Streptoccocus suis (S.suis) is a zoonotic disease mainly in pigs which can cause

serious infection in humans through exposure with pigs and consumption of raw

- pork. Thailand is the country with highest cumulative incidence of S.suis infection. However, no study has investigated the cost-of-illness from *S.suis* treatment and factors affecting the treatment costs in Thailand.
- This study aimed to estimate the direct medical costs associated with S.suis treatment in Thailand and identify key drivers affecting high treatment costs from the provider's perspective.

Methods

- A retrospective analysis of the 13-year data from 2005-2018 of confirmed S.suis patients admitted at Chiang Mai University Hospital (CMUH) was conducted.
- The multiple imputation with predictive mean matching strategy was employed to deal with missing data.
- Generalized linear models (GLMs) were used to forecast costs model. The modified Park test was adopted to determine the appropriate family.
- All costs were inflated applying the consumer price index for medical care and presented to year 2019.

Results

Table 1 Patient characteristics

Characteristics	Total (n=130)		
Age (year) (mean±SD)	56.32± 13.77		
Male	89 (68.46%)		
Female	41 (31.54%)		
GCS†	12.65± 3.15		
SAPS II	27.22± 13.93		
Risk behaviours			
 Alcohol drinking 	66 (50.77%)		
 Consumption of raw pork 	49 (37.69%)		
 Recent contact with pigs/pork 	5 (3.85%)		
exposure			
 Pig related occupation 	3 (2.31%)		
- Skin injury	2 (1.54%)		
Signs and symptoms			
 Neck stiffness 	46 (35.38%)		
- Diarrhea	37 (28.46%)		
- Vomiting	27 (20.77%)		
- Vertigo	10 (7.69%)		
Major clinical manifestations			
- Septicemia	73 (56.15%)		
- Meningitis	48 (36.92%)		
- IE	34 (26.15%)		
- Septic shock	20 (15.38%)		
Outcomes			
- Recovered	68 (52.31%)		
 Recovered with sequelae 	43 (33.08%)		
 Having valve replacement 	16 (12.31%)		
- Death	16 (12.31%)		
Mean length of stay (days)††	18.27± 17.26		

GCS, Glasgow coma scale; IE, Infective endocarditis; SAPS II, The Simplified Acute Physiology Score

Note: †Available data from 101 patients; ††Available data from 128 patients

Results

- Among 130 *S.suis* patients (89 males, 41 females), the mean age was 56.32 ± 13.77 years. Septicaemia was the most common clinical manifestation (56%), followed by meningitis
- (37%) and infective endocarditis (26%).
- About half of patients recovered from the infection while around one-third had sequelae.
- The average admission duration was 18 days.

Table 2 Direct medical cost of *S.suis* treatment in the year 2019 value

Cost variables	Mean in THB	SD	Median	IQR
	(US\$)			
Overall (n=130)				
Medications	30,321.75 (US\$ 976.64)	61,930.05	8,132.181	4,223.40-
	(, ,			23,588.58
Laboratory tests	13,187.22 (US\$ 424.75)	14,195.96	8,087.821	4,820.37-
	(,			16,670.44
X-ray	8,239.51 (US\$ 265.39)	12,487.7	4,039.29	714-9,828
Others (Room charges, meals,	72,926.03 (US\$ 2,348.89)	98,299.8	24,231.56	94,65.50-
staff services, medical devices)	(= -, = , = , = , = ,			99,540.23
Average cost	124,674.51 (US\$ 4,015.67)	168,825.40	47,213.39	25,136.02-
per episode				182,052.60
Total	16,207,676.40 (US\$ 522,037.12)			

Table 3 Cost Model of *S.suis* treatment

Variables	Unstandardised Coefficients		t	Significant	95% Confidence	
				level	Interval for B	
	Beta	SE			Lower	Upper
					Bound	Bound
Constant	333637.8	164,836.2	25.74	< 0.001	126687.2	878653.4
Infective	2.417703	0.4773245	4.47	< 0.001	1.641917	3.560039
Endocarditis						
GCS	0.9162752	0.0259905	-3.08	0.002	0.8667249	0.9686582
Length of	1.037278	0.0064089	5.92	< 0.001	1.024792	1.049915
stay						
Bicarbonate	0.9512553	0.0195557	-2.43	0.015	0.9136888	0.9903663
(mmol per						
litre)						

- The average total direct medical cost was 124,675 Thai baht (THB) (US\$ 4,016), of which most expenses were from the "others" category (room charges, staff services and medical devices).
- Infective endocarditis (IE), GCS, length of stay, and bicarbonate level were significant predictors associated with high total treatment costs.
- Overall, marginal increases in IE and length of stay were significantly associated with increases in the total costs (standard error) by 132,443 THB (39,638 THB) and 5,490 THB (1,715 THB), respectively.
- In contrast, increases in GCS and bicarbonate levels were associated with decreases in the total costs (standard error) by 13,118 THB (5,026 THB) and 7,497 THB (3,430 THB), respectively.

Conclusions

- IE, GCS, length of stay, and bicarbonate level were significant cost drivers associated with direct medical costs.
- Patients' clinical status during admission significantly impacts the outcomes and total treatment costs.
- Early diagnosis and timely treatment were paramount to alleviate long-term complications and high healthcare expenditures.



